Lactobacillus Plantarum Strain 299V
Acute Graft Versus Host Disease
Children's Oncology GroupPhase 3Active
B
59/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 44/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Acute Graft Versus Host Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
METHOTREXATE Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Phase 4 | BB |
Basiliximab Zhongming Zhang | Phase 4 | BB |
TACROLIMUS Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Phase 4 | BB |
Ruxolitinib Xenikos | Phase 3 | B |
Cyclophosphamide Stanford University | Phase 2 | B |
View all 14 →
Same molecule, other indications
Lactobacillus Plantarum Strain 299V is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →